Modular electronic inhaler

ABSTRACT

A modular electronic inhaler having an embedded system and a method for precise and repeatable delivery of multiple types of medications in different forms to the pulmonary system of a human user. The inhaler can include a first MDI housing defining an internal chamber for accommodating a MDI medication cartridge and a second DPI housing defining an internal chamber for accommodating a DPI medication cartridge. Meter reservoir compartments in each housing can automatically provide precise doses of medicine using vacuum pressure sensors. The sensors can be in communication with the internal embedded system/electronics (microcontroller) of the inhaler and the electronics/microcontroller can be in permanent communication with a software application running on the user&#39;s smart phone or other electronic device.

This application is a continuation-in-part of U.S. application Ser. No.17/140,348, filed Jan. 4, 2021, which application claims the benefit ofand priority to U.S. Application Ser. No. 63/198,203, filed Oct. 2,2020, all of the above-identified applications are incorporated byreference in their entireties, as if fully set forth herein, and for allpurposes.

1. FIELD OF THE DISCLOSURE

The disclosure relates generally to inhalers and more particularly to anovel complex embedded system for an electronic inhaler which provides amethod and device for precisely delivering liquids and/or powdersefficiently to the pulmonary system of a patient/user while providingfeedback to the patient, as well as to a novel modular electronicinhaler.

2. BACKGROUND

Currently devices for treatment of respiratory diseases, such asinhalers, use aerosol delivered through inhalation creating a majorchallenge for providing accurate medicine delivery and dose verificationbased on the prescribed dose. Elements to consider for an inhaler deviceusually are delivery, inhalation of prescribed dose, dose verification;incorrect administering of a dose or patient misusing the dose.

For most inhaler systems today, including medicine aerosols, use largesizes of medicine molecules for their fluids and usually high speeds offluid delivery. The high speeds of medicine delivery in such systemsoften does not allow the medicine to reach the bottom of the patient'slungs. Instead, because the speed is too high the medicine typicallystops and is deposited in the patient's mouth and/or throat. As such, agood portion of the medicine administered with current inhalers often islost. One approach to overcome this inconvenience is to increase thedosage amount. Increase of dosage amounts is not a favorable solution,as it potentially opens the door for unwanted side effects.

The high speed of medicine delivery mainly from the pressurizedcartridge (reservoir) usually leads to a cooling effect (i.e. acondensation), and often causing the last crystallization of medicine todeposit on the exit side (i.e. mouthpiece) of the inhaler device. Wherethis occurs, repeated cleaning and disinfecting of the inhaler devicesis required, which can lead to the end part of the inhaler mechanism tobe damaged.

Accordingly, there exists a need for an inhaler device which overcomesor reduces the above-identified problems with current inhalers. Asdiscussed below, the current disclosure addresses these problems byproviding an embedded electronic inhaler which provides for an efficientmode to administer liquid and/or powder medicine, with precise dose andconsistency, and while also being in electronic communication with asoftware app downloaded on the patient/user's smart phone or otherelectronic device for providing validation and feedback to patient,pharmacist, doctor, while also managing dosage types, amounts andadministering times.

SUMMARY OF THE DISCLOSURE

Generally disclosed is a novel electronic inhaler and novel modularelectronic inhaler with both having an embedded system to deliver liquidand/or powder medicines to the pulmonary system of the user. Thedisclosed novel inhaler may include: a housing defining an internalchamber for accommodating at least two different types of medicinecartridges, such as but not limited to, a cartridge containing powdermedication and a cartridge containing a liquid medication, As anothernon-limiting use embodiment, two cartridges can be used with bothcontaining powder or liquid medications, but with the medications beingdifferent from each other. Preferably, the installed cartridge(s) can beconnected to or otherwise in communication with a measure reservoircompartment (MRC) for receiving a virtually exact and precise prescribeddosage amount.

Each cartridge (medicine reservoir) may have a bar code or a rewritablememory chip containing the following information: (a) the type ofmedication (b) the temperature of the solution, (c) density of themedication, (d) solution pressure, (e) viscosity. Once the cartridge isplaced within the internal chamber of the housing the embedded systemcan read/detect the cartridge information, which can be displayed on theuser's phone and/or other electronic device display, such as, withoutlimitation, a computer desktop or laptop display. The displayedcartridge information can include, without limitation, medication type,administering mode and dose value. Where the cartridge medicationcorresponds with the prescription, the cartridge can be consideredvalidated and can be activated by the software of the embedded system.The embedded system can be provided with electronic circuits. Amicrocontroller component of the electronics can read and detect all ofthe information and based on its algorithm can decide and provide forthe best “use” output for the device. The microcontroller can be inbidirectional communication with the user's phone app, as well as inelectronic communication with an electronic system of a doctorand/or/pharmacy in order to receiveprescriptions/recommendations/guidelines, preferably at all times. Basedon the medication density value information received from the cartridge,the microcontroller can calculate and release the prescribed dose in avirtually precise manner. Knowing the mass value of the dose prescribeand the density of the medicine, the microcontroller can be programed tocalculate using the formula (volume=mass/density) an exact volume ofmedicine to be released in the measurement reservoir compartment (MRC).

The pressure/vacuum sensors preferably located on the mouthpiece sectionof the inhaler device can be in communication with the microcontroller.Once a difference in pressure and/or vacuum is sensed by the sensors,the liquid or powder medication can be released through a launch padcomponent. The launch pad (LP) can be part of the embedded system andcan preferably connect to the medicine reservoir compartment (MRC)within a cavity area of the mouthpiece. The LP can act as a spacerand/or can move up and down within the mouthpiece for eliminating orremoving deposits and/or dirt contained in the mouthpiece and forcreating energy by increasing pressure in the MRC.

An actuator valve located at and/or on the end of launch pad (LP) can becontrolled by microcontroller. In certain non-limiting embodiments, theactuator valve can be an electro mechanic mechanism, piezoelectric,induction and/or electromagnetic actuator. In use, the actuator valvecan be designed to puncture the medication cartridge or otherwiserelease the prescribed dosage for the liquid or powder medication fromits medication cartridge for ultimate entry into the patient's pulmonarysystem through use of the disclosed novel electronic inhaler.

The LP can be chosen and designed to affect the pressure and the speed(velocity) of the liquid and/or powder medication with respect toBernoulli Effect and Coanda Effect to maximize the efficiency fordelivering the liquid and/or powder medications under controlledpressure and velocity.

In another non-limiting embodiment, a novel modular electronic inhaleris also generally disclosed and shown and can have an embedded systemfor delivering liquid and/or powder medicines to a user's pulmonarysystem.

For purposes of this disclosure, the definition of “fluid” is consideredto cover liquid, air, dry powder in air or gas and/or aerosols and alsoincludes any substance whose shape can be affected by external pressure.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure will be more clearly and easy understood based on thefollowing drawings description:

FIG. 1 is a cross sectional view of the novel electronic inhaler inaccordance with the present disclosure;

FIG. 1A is cross sectional view similar to FIG. 1 though illustrating adifferent mechanism for disaggregating the powder mixtures;

FIGS. 2A, 2B and 2C illustrate a first non-limiting embodiment for thelaunch pad and how the air flow characteristics are changed based on theBernoulli effect and Coanda effect, while also showing the launch padmovement on the measurement reservoir compartment;

FIGS. 2D, 2E and 2F illustrate a second non-limiting embodiment for thelaunch pad and the influence of air flow velocity, pressure andtrajectory with respect to the Bernoulli and Coanda effects;

FIGS. 2G and 2H illustrate another embodiment for the geometry of launchpads

FIG. 3 is a summary block diagram of all the preferred components forthe disclosed novel electronic inhaler and the preferred way theyinteract and communicate with each other in accordance with the presentdisclosure;

FIG. 4 is a block and flow diagram for the network and flowinterconnection at different levels in accordance with the presentdisclosure;

FIG. 5 is a block diagram of the logic and interconnection between thenetwork, microcontroller and the flow interconnection of certain of theinhaler components in accordance with the present disclosure;

FIGS. 6A and 6B illustrate a method and alternative position for thelaunch pad to provide for a third source of energy of the novel inhalerin accordance with the present disclosure;

FIG. 7 is a cross sectional view of the novel electronic inhalerincluding the mechanism of compression in accordance with the presentdisclosure;

FIG. 8 illustrates a cross-sectional view of another embodiment for aninhaler and in particular to a modular electronic inhaler in accordancewith the present disclosure; and

FIG. 9 illustrates a cross-sectional view of another embodiment for amodular electronic inhaler in accordance with the present disclosure.

DETAILED DESCRIPTION

The disclosed inhaler with embedded system can have a housing (100; FIG.1), containing a mouthpiece (99; FIG. 1) having attached preferably atleast two pressure/vacuum sensors (109; FIG. 1)(though such number isnot considered limiting), and preferably a total of four sensors, thoughsuch is also not considered limiting. In one preferred embodiment, thehousing and mouthpiece can be constructed integral or monolithicallyformed to form a one-piece member, though it is also within the scope ofthe disclosure that the housing and mouthpiece can be separate piecesthat are connected together during use.

Preferably at least two different types of medication cartridges, and apreferred total of four cartridges, can be disposed or accepted withinthe internal chamber of the housing, though such is not consideredlimiting, and other number of cartridges and medication types can beused and are considered within the scope of the disclosure. The noveldisclosed modular system can accommodate different types of cartridgesand/or custom cartridges. Where four cartridges are received within thehousing, preferably an equal number of cartridge readers (i.e. fourcartridges readers) can be provided and can be in permanentcommunication with the microcontroller. The housing can have integratedwithin at least one vibrator for mixing the DPI cartridges ifnecessarily. One or more batteries can also be included within housingfor powering at least the electronics which can also be disposed withinthe housing. Preferably, the electronics can have integrated wirelesscommunication technology, such as, but not limited to, one or more ofthe following: Bluetooth, Zigbee, Wi-Fi, LTE, 5G, IOT, infrared, etc.).Where the batteries disposed within the housing are rechargeable,charging technology can also be provided as part of theelectronics/embedded system. Alternatively or additionally to usingrechargeable batteries, extended life batteries can be used for theinhaler's power source.

The software for the embedded system and/or App downloaded on the user'ssmart phone can be a platform application including a database and apreferred required authentication and/or authorization to access anaccount linked with a unique ID production tag. The communicationinterface between the embedded system of the inhaler and the softwareplatform can be designed with two levels of priorities, though suchnumber of priority levels is not considered limiting.

Level 1 can be set and/or updated/downgraded by a doctor or pharmacist.Preferably, the dosage, frequency, calendar, timing, etc. for thepatient's medication can be programmed/entered by the patient's doctoror pharmacist to avoid or reduce possible mistakes from being made. Oncea medication is delivered through use of the disclosed inhaler andconfirmed, the saved settings can block the particular medication frombeing delivered again. Preferably, delivery can only occur per thepreferred doctor/pharmacist entered/programmed schedule for the patient.

Level 2 can allow the patient to receive feedback and requests. However,preferably the patient still cannot modify the dose quantity, thefrequency or schedule.

Doctors and/or pharmacists associated with the patient will preferablyhave access to a website or other online access where they can set thedosage, the frequency of dose administering, the type of medicineprescribed and other related information for each patient, as well asmake any necessary changes or modification thereto. All of the enteredinformation for the particular patient can be automatically communicatedwith or transmitted to the microcontroller of each patient's inhalerand/or the App running on each patient's smart phone, for proper dosageand scheduled settings. In case of side effects or other issues, thedoctors have the ability to change the dosage and the frequency ofmedicine administering, as well as switching the patient's medication.

The software within the microcontroller and/or of the smart phone Appcan control the activation of cartridges based on confirmations andvalidations with the type of medication prescribed.

More details about the components interaction and interconnection arepresented in the diagram shown in FIG. 3.

The disclosed novel inhaler provides an apparatus and method to properlydeliver an accurate dosage of medication. The novel approach caninclude, without limitation, that the cartridges used (medicinereservoir, container, capsule compartment) can be provided with barcodesor IC chips (Integrate Circuit) (103) with the information of themedicine, density, and pressure fine particles fraction and temperatureof fluid, as well as any other information deemed necessary forproviding proper, timely and safe medication administering to thepatient using the disclosed novel inhaler. Once the cartridges,regardless of type (the functionality will preferably be the same) (i.e.either Metered Dose Inhaler (MDI) or the Dry Powder Inhaler (DPI) (104a; 104 b, respectively FIG. 1.)) are inserted within the housing of thedevice (100; FIG. 1), an electronic reader (barcode or memory chip) canbe provided to extract the information from the bar code/IC chippreferably on the outside of the cartridge and sends the information tothe electronics (106; FIG. 1) and specifically to microcontroller. Theinhaler preferably has a Measure Reservoir Compartment (MRC), (102 a;102 b; FIG. 1) in direct communication with the cartridges and LaunchPad (L.P.). The role of the MRC is to receive and stock/store anaccurate dose of preferably prescribed medication/vitamins/supplements,etc. right before it is released. Knowing the dose prescribed (mass inmg or ml; knowing 1 g=1 ml) and already knowing the density of themedication, the microcontroller can calculate the volume of fluid(volume=mass: density). The algorithm of the microcontroller will openthe flow control valve (110; FIG. 1 or FIG. 1A) of the cartridge for aspecific time equivalent for the dose calculated and prescribed. Thisapproach provides feedback and allows the microcontroller/downloadableApp to know how much medicine is in the cartridge at any moment and alsothe second that a successful dose has been administered to the patient.The medicine preferably travels from the cartridge to thecorresponding/associated MRC. The MRC has the correct dose and from herethe fluid travels to the corresponding/associated launch pad LP and isejected through or into a homogenized area (98; FIG. 1) where it ismixed with the airflow from aperture (200; FIG. 1) created by patientinhalation; causing the medication to enter the patient's pulmonarysystem through mouthpiece 99.

Valve 110 can open the cartridge (i.e. punctures, pierces and/or createsa temporary opening) stored in the associated cartridge chamber and letsa specific quantity of liquid or powder to go on (i.e. enter into) theassociated MRC after the trigger switch is activated. The trigger switchcan be a proximity sensor, tactile/touch sensor, on/off mouthpieceswitch which can be triggered by the removal or replacement of a covercap for the mouthpiece, or any other switch or sensor which can causeenabling of the inhaler for use upon sensing or determining that thecover cap has been removed from the mouthpiece and/or alsodisengage/deactivate the inhaler when the cap is returned or placed backon to the mouthpiece, etc. The valve can be flow controlled andactivated by the microcontroller.

The launch pad part of the embedded system can be designed to have areduction in pressure which occurs when the fluid speed increases and tohave a reduction in speed occurring when the fluid pressure increases.This is based on the known Bernoulli equation. The launch pads have adifferent design (i.e. as compared to each other) based on viscositytypes of medicine mix is intended to be used (101 a; FIGS. 2A and 2B)and (101 b; FIGS. 2E and 2F) with the specific launch pad.

The fluid traveling through the launch pads can have their velocitydecreased (beneficial for eliminating any deposits to improve the flowand allowing the medicine to go deeper down into the patient's pulmonarysystem). At the quantum level, fluids and solids are substances forwhich the interaction between their constituent atoms or molecules isgoverned by the laws of quantum mechanics.

As a fluid stream passes through an opening in a wall, eddies appearbehind the wall. The particles part of the fluid has a componentdirection of velocity that is larger than other component velocities,but as they interact with each other and other particles in the flow,they will move on a circular path. These processes result in a vortexeffect.

In other embodiments of the disclosure, the device can be used with avariety of medicines, and drug delivery types, considering the positiveeffects of any fluid passing through the launch pad, and being affectedby the vortex resulting in homogenizing all of the particles on thefluid and target to a path, changing the velocity and pressure.

The design of the disclosed inhaler can lead to a big improvement in theflow of particles to reach the lower side of the patient's pulmonarysystem and the complete bronchial tree.

Another embodiment of the disclosed device is directed to the way thefluid is influenced by passing through the launch pads directly relatedto pressure, velocity and trajectory (FIG. 2C and FIG. 2D).

In another embodiment, a method for drug delivery is the injector and/orejector assembly which can allow the medication dose to be administered,and can include a valve actuator which can include, but it not limitedto, piezoelectric, shape memory alloy, lab on chip, magnetic,electromagnetic, spring, valves 150 and 151 (See FIG. 1) preferablydirectly coupled to an aperture of an associated launch pads 101 a and101 b, respectively. The valve actuators can be in direct communicationwith the electronics of the inhaler and the microcontroller can controlwhen to move the valve 150 and/or 151 (i.e. the moment to open/close thevalve) for efficiently administering the dose.

The inhaler can also control the on/off valve (150; 151; FIG. 1) by themicrocontroller allowing the ejection of fluid on fast short sequences.The microcontroller can preferably have 5 different frequencies inmemory and an algorithm can pick which frequency to use based on thesize of Fine Particles Fraction (F.P.F.) dose prescribed. A higher orlower number of frequency choices above 5 frequencies can also be useand are also considered within the scope of the disclosure.

The embedded system of the inhaler may include one or more vacuum,pressure, and/or differential pressure sensors (109; FIG. 1) to engageon automatic breath actuation. The inhaler device may include anaperture 200 (See FIG. 1) at the opposite side of mouthpiece andproviding a passageway and communication between aperture 200 and thehomologizing area of mouthpiece 98. Though not limiting, aperture 200can be centrally located with respect to housing 100, and preferablycreates a flow of air when the process of inhalation starts. In this waythe resistance is reduced resulting in easier inhaler use by children,elderly, handicapped, ill patients, etc.

Preferably, the patient can generate a peak inspiratory flow to reach apreset threshold for the microprocessor to release the medicine, throughthe launch pad and opening the L.P. valve(s) in the desired frequency.In accordance with embodiments of the disclosure, a Mass Air FlowSensor, not shown, can be added to device and in direct communicationwith the microcontroller to increase the precision on reading the flow.

The disclosed device can be provided with several features offering aunique inhalation control taking in consideration the aerodynamics ofthe launch pad design and the influence at the atomic and molecularlevel of the liquid or powder, characterized by low airflow resistanceand a smooth increase of pressure at higher flow rates duringinhalation. The vortex effect created when the fluid passes through thelaunch pad and sequential release of fluid by the ejected mechanism andtravel to the homogenized area will help to ensure a high qualitymedication (fluid) release. The patient and doctor can be provided withfeedback or other information regarding the patient's use, so that theyknow that the prescribed dose of the drug was delivered, know that thenecessary flow was achieved, and the medication was successfullyadministered to the patient. The patient and doctor can also know howmany doses were taken, how much drug is left in the cartridge, when thelast dose was administered, and what date/day and/or time is scheduledfor the next dose administering.

The inhaler device can also help to ensure the accurate dose delivery ofdrug in accordance with the doctor's prescription through the use of theflow control valve (preferably placed between the cartridge and measurereservoir compartment M.R.C.) and microprocessor algorithm. Thecartridges can be design for breath activated, refillable, multi-useoperation (with or without propellant).

The inhaler can disperse the powder mixtures into a respirable fine drugparticle fraction by aerodynamic means. The aerodynamic behavior of aDPI can be affected by its design, dimension, and the geometry of thefunctional engineered device parts, such as the air-inlet/air-outlet,inhaler resistance, mechanisms of disaggregating powder mixtures andemptying the dose. For instance, the air-inlet size has been shown tohave a significant impact on powder dispersion at different inhalationflow rates by varying the inlet jet flow turbulences and particleinteraction velocity. The performance of the inhaler device can also bemodified by the resistance to airflow, which can have a direct impact onthe peak inspiratory flow, acceleration rate, inhaled volume to reach,and total inhalation time.

In one non-limiting embodiment, referring to FIG. 1, electronic circuit106 is shown with a microcontroller and wireless communication module.The device may be in communication with other electronic devices viaBluetooth or other wireless technology. A power charger and batteries108 is shown and the device can have a vibrator or vibrating mechanism107 for keeping the liquid and/or powder mixed.

The network and communication of the disclosed inhaler device can havetwo levels of priority and access, though the number of levels is notconsidered limited to two levels.

The embedded system may have a server/main network (400; FIG. 4) whereall the data is preferably recorded and stored in a database and can beaccessed by the doctor (401; FIG. 4) and/or pharmacist (402; FIG. 4) toread the history of a specific patient and prescribe new/old medication,including the dosage and schedule for administering of the drug. Thedoctor and pharmacist can be considered part of level 1 in the network,and they can preferably have authority to change a prescription (exampleif patient has a side effect) or increase/decrease the dose and/orchange or adjust the schedule for administering. The novel inhalerdevice (405; FIG. 4) may communicate directly via App running on thepatient's, patient's caregiver's, etc. phone or other electronic device(i.e. portable electronic device, PC, etc. all collectively referred toas “Phone” or “phone”) (404; FIG. 4). Phone 404 may access main server400 via a network getaway 403 (FIG. 4). Inhaler device 405 may also beable to communicate directly with main server 400 via the networkgateway. Phone 404 can have preloaded all the information regarding thedose and administering schedule, and notifications for the time ofadministering. In case the patient does not take any action after threenotifications, the app can send one or more notification alerts to thepersons listed as emergency contacts. The app can collect, keep andelectronically send the information to main server 400 in regards witheach dose taken successfully, each missed dose, how much medicine isavailable in the cartridge, and how many doses were missed based on theprescribed schedule and some or all of such information and anyrevisions/modifications based on such received information can be storedin the database associated with the server/main platform 400. In thisway the patient can have feedback and information regarding thetreatment, and the doctor/pharmacist can see and check at any time tosee how the patient is following the schedule.

The particles needed to be administered can be based on theirgeometrical diameter, density, and morphology with these propertiesgenerally being manipulated during the manufacturing process. Due tointer particulate forces, mechanical interlocking, capillary,electrostatic, and van der Waals forces, micronized powders are veryadhesive/cohesive, spontaneously forming agglomerates.

The extent of the partial and consequently of the combined forces isdependent on powder properties such as particle size, morphology, shape,and material, as well as on environmental factors, such as relativehumidity. Since the extent of agglomeration negatively affects thefraction of the inhaled powder, which is within the respirable range,these agglomerates preferably should be effectively deagglomerated priorto or during the processes of aerosolization and inhalation.

The novel inhaler addresses deagglomeration through a homogenized oropen/cavity area (collectively “homogenized”) (98; FIG. 1), where thegeometry of the functional device parts on the exit side of the launchpads are influenced by the airflow coming from aperture (200; FIG. 1)create a torsional vortex. In this way the aerodynamic behavior ofpowder particles is changed, and they may be homogenized for theprocesses of inhalation.

In FIG. 1 the aerodynamic effect against the fine particle fraction ofmix is achieved based on cavities and chambers geometry design (based onCoanda effect), illustrated on homogenized area 98 (FIG. 1). The effectcan be created by the interaction of forces of airflow from (200;FIG. 1) and powder exiting (101 a or 101 b FIG. 1) resulting in atorsional vortex.

In FIG. 1A a different approach of the aerodynamic behavior of the fineparticle fraction is provided. This effect can be achieved based onchanges on the geometry of the functional engineered device parts andthe design (98; FIG. 1A). The powder exiting from launch pads (101 a or101 b FIG. 1A) can be forced into the internal barriers 137 (preferablyelliptical or oval in shape though not considered limiting and othershapes can be used and are considered within the scope of thedisclosure) and wall barriers 129 and into opening 131 (preferablydefined between wall barriers 129 and preferably centrally located) andinteracting with the air flow from aperture 200 FIG. 1A will create atorsional vortex. All of this can be in total interconnection with thegeometry design of the launch pads with respect to Bernoulli equation,and Coanda effect regarding aerodynamic trajectory. The vortex effectcreated at the quantum level, the torsional vortex created on 98 areaFIG. 1, the aerodynamics of the launch pads and the sequential release(150; 151; FIG. 1A) can all be applied to the powder mixture todisaggregate the powder and homogenate the mix, making the mix ideal orotherwise improved for inhalation.

The described inhaler with embedded system can have a non-limitingadvantage of utilizing a patient's inspiratory airflow as the mainsource of energy so that the device can be breath actuated. Thisinherently avoids the need to synchronize the actuation and inspirationmaneuver by the patient.

In another non-limiting embodiment, a patient's inhalation (breathingpattern) can be simulated by adding a miniature turbine on the aperture(200; FIG. 1) or passageway 201 and being controlled by themicroprocessor and activated at a specific airflow value. The device canhave a decrease in resistance with a more efficient way to deagglomeratethe particles in the fluid.

Another advantage of the inhaler with embedded system is once thecartridge device is activated and the dose is released in the measurereservoir compartment (MRC), it can ensure or at least help to reducethe chance that the mechanism does not cause an accidental release of anadditional dose or additional medication.

The disclosed inhaler with embedded system may have three sources ofenergy. The first form of energy can be the patient's inspiratoryairflow. Second, the miniature turbine, not shown in the drawings, canbe located within aperture 200 or the passageway 201 associatedtherewith (FIG. 1) and controlled by the microprocessor and powered bythe system's existing batteries. A third source of energy may be createdby compression resulting from moving the launch pad down into the MRCcompartment, as illustrated in FIG. 2A and FIGS. 2E and 2F.

If two different cartridges with two different medications areinstalled; both cartridges can be preferably validated, and aftervalidation the cartridges can be activated, preferably based on theentered or programmed administering schedule. Based on the doseschedule, each cartridge will be preferably ON one at a time, with oneexception being where medications from multiple cartridges are to betaken at the exact same time. In cases where both medications need to beadministrated simultaneously, but not necessarily at the exact sametime, the doctor and/or pharmacist preferably prescribes whichmedication should be taken first.

If the dose prescribed is larger than the volume of measurementreservoir compartment (MRC), the microcontroller can divide the doseinto two equal rations and the medication will be taken in two steps, orthe doctor can prescribe a cartridge with higher medicine density.

The system presented in FIG. 5, has three interconnected components:

-   -   1 network and communication with the device (N)    -   2 device logic functionality (D)    -   3 feedback and alerts (F)

Once the doctor prescribes a medication, this prescription can bewritten directly on the main platform for each patient (401; 400; 403;FIG. 5). Each patient preferably logs into the main platform from anyPC, laptop and/or mobile electronic device for authentication and typeor scan the serial number for the specific novel inhaler device thatthey are using. After these steps are performed, the phone applicationcan be preferably download (from the server) and preferably the App canbe preloaded with all the information regarding prescription medicationtype, dose value, density viscosity, temperature of medication, type ofcartridges use, schedule notification time, thresholder for time fortaking the medication etc. It is also within the scope of thedisclosure, that the App is first downloaded and then the patient signsinto the App to receive his or her specific medication/prescriptioninformation that has been preferably entered by the patient's doctorand/or pharmacists, or a hospital/clinic/urgent carefacility/psychologist, etc.

At this moment in time, full communication between the device, the phoneapp and main platform is preferably provided (106; FIG. 5).

Once the cartridges (104 a; 104 b; FIG. 1) are inserted in the device,its IC memory (103 FIG. 5) can be read by a device reader (103 r; FIG.5) to begin the validation process (120; FIG. 5). If the cartridgesdon't correspond with the prescription, the doctor/pharmacist, etc. canbe alerted or otherwise notified and the cartridges preferably will notbe activated. If the information collected from the cartridgescorresponds with the prescription, the cartridges will be validated andactivated (121; FIG. 5) and considered to have an ON function from themicrocontroller; calculating the dose value and schedule time (122; FIG.5).

The next step preferably involves determining if there is enoughmedication in the cartridges (123; FIG. 5). If not, thedoctor/pharmacists, etc. can be alerted or otherwise notified of thisshortage (124; FIG. 5) and the prescription can be refilled (125; FIG.5).

If there is a sufficient amount of medication in the cartridge, theinhaler device can be on standby waiting for the dose scheduled deliverytime notification (134, FIG. 5). If the patient takes no action (135;FIG. 5) when the notification is alerted or otherwise provided,specifically after at least two notifications are ignored, the softwarecan then automatically call or otherwise their previouslydesignated/configured emergency contact (136; FIG. 5). All of thesealerts can be in communication with and/or controlled by themicrocontroller (106; FIG. 5) and a record of all notifications and anypatient's actions or inactions thereto can be stored in the database.When the scheduled time is due, and the patient uses the device forinhalation, a proximity sensor can preferably engage (119; FIG. 1) (orwhile they are removing the cap on the mouth piece, or an on/off switch,only in the scheduled time in a threshold interval, preferably between15 minutes to 30 minutes—though such range is not considered limiting)can open the valve (110; FIG. 1) reassessing the calculated dose in themeasurement reservoir compartment (MRC) (133; FIG. 5).

When the patient starts inhaling through the device, the sensors (109;FIG. 1) preferably sense such activity and can trigger the functionprocess of the device including causing the operation of the inhaler formedication administering to automatically start. The precise dose can bepreferably already in the measurement reservoir compartment (MRC) andwill travel to the launch pad (LP) by opening the valves (150; 151 FIG.1), (130; FIG. 5) in specific sequences based on the viscosity of powderprovided by the information from (103; FIG. 1) and processed by themicrocontroller. Preferably simultaneously, the mini-turbine located onaperture 200 or within passageway 201 (FIG. 1) can be started/activated(131; FIG. 5) and the mass air sensor (MAS) starts sending informationto the microcontroller (132; FIG. 5). The powder can be preferablyreleased to area (98; FIG. 1), for the deagglomerating process and thehomogenizing process with the air coming from aperture 200 and/orpassageway 201 (FIG. 1). A mass air sensor (MAS) will technicallyvalidate if the dose was successfully administrated (126; FIG. 5) basedon the value and time of the patient's inhalation. All the readingsranging between 75% to 100%, based on the value and time recorded bypatient's inhalation can be considered a successfully administrated dose(128; FIG. 5), though other ranges can be used and are also consideredwithin the scope of the disclosure. These readings and percentages canbe visually displayed on the phone app (404; FIG. 5), recorded on/storedwithin the database of the main platform (400; FIG. 5), and the dose canbe subtracted from the previous value to accurately determinate themedication remaining in the cartridge (123; FIG. 5). If the dose isrecorded as incomplete or not successfully administrated or otherwisemissed (127; FIG. 5), the recording process can still subtract from theprevious value. In case the patient obtains three continuous,unsuccessful dose recordings, the server can send a notification to thedoctor and emergency contacts. Other high or lower numbers of continuousunsuccessful dose recordings can also be used and are considered withinthe scope of the disclosure.

The device housing (100; FIG. 1) may accommodate cartridges in differentsizes; small, medium, and large as one non-limiting example.

The entire administration dose process may be monitored in real time ondisplays of the phone or PC devices, including the feedback and/ornotification.

In some circumstances, patients may have to take five or more differentmedications with some in dry powder and/or some in liquid form. Thedisclosed inhaler with embedded system will be able to provide thepossibility of using multiple cartridges with either or both dry powderor liquid form. The device has the capacity of holding four differentmedications in different forms in one embodiment and in anotherembodiment two different cartridges can be provided within the device,though the number of medication cartridges are not considered limited toany specific number of cartridges.

As a non-limiting example, two cartridges may have different medicationsin different forms and be inserted in device (104 a; FIG. 1), MeteredDose Inhaler (MDI), and (104 b; FIG. 1) the Dry Powder Inhaler (DPI). Inthis non-limiting example, the general process for use can include,without limitation:

-   -   (1) the cartridges can be validated based on the prescription        for the patient;    -   (2) the cartridges are activated; and    -   (3) calculating the dose for each cartridge and schedule the        time for notifications based on the patient's prescription for        each medication.

During the scheduled time, a notification can be sent to the phone,watch, pager, pc device etc. This notification can be for a specificmedication, for instance, for the MDI (104 a; FIG. 1). When the patientobtains the device in hand to perform the dose administration, the (119;FIG. 1) sensor will trigger and only cartridge (104 a; FIG. 1) will beactive ON (all others will preferably be in an OFF state). The openingof valve 110 (FIG. 1) will release the calculated dose from thecartridge to MRC. This process can be preferably quick, automatic, andoccurs right before the patient starts the inhalation.

Patient inhalation will be read or otherwise sensed by sensor(s) 109(FIG. 1), and will automatically and simultaneously trigger or otherwisestart the following (i) open valve 150 (FIG. 1) at a specific sequencedrate, allowing medication traveling from MRC (102 a; FIG. 1) to LP (101a; FIG. 1); (ii) preferably start mini-turbine (when provided) locatedat aperture 200 or passageway 201 (FIG. 1), (iii) start reading the MAS,and (iv) releasing the measured dose in homogenized area (98; FIG. 1).

When a new notification is received for different cartridges, forinstance, the DPI (104 b; FIG. 1) only (104 b; FIG. 1) will preferablybe active ON and the process will be similar to the one described above.

Each cartridge can preferably be individually active ON one at a time,based on the prescription dose administrated time schedule.

The disclosed novel inhaler device can be modular with detachable andinterchange mouthpiece. In one non-limiting embodiment, to clean thedevice and eliminate any interaction between different medicine and/ordeposits inside inhaler, a cleaning cartridge can be provided which willhave a specific code and once is place on the device the microprocessorcan automatically start the cleaning process

A third source of energy may be created by compression resulting frommoving the launch pad down into the MRC compartment, as illustrated inFIGS. 2A, 2B and 2C, FIGS. 2D, 2E and 2F, FIG. 6, FIG. 1 and FIG. 7.

The movement of LP (101 b) down on MRC 102 b), will create a compressionand, specially for dry powder DPI, can provide for improved patientinhalation. Often for DPI, the patient is instructed to take a fastinhalation or may be two or three repetitive hard inhalations. The novelembedded device of the inhaler described herein can create acompression, increasing the pressure in MRC (102 b), which in additionto gravity (refers to the position of inhaler in use and the placementposition of the cartridge, applying gravitational force to medication)can increase the pressure of medicine delivery simultaneous with theBernoulli effect created on the LP (102 b). Thus, pressure and velocitycan be controlled, allowing the patient to not make any efforts (orreducing the patient's involvement) for the inhalation process.Furthermore, the patient doesn't require a learning process for usingtwo different types of inhalers (i.e. 1. liquid and 2. dry formmedication).

Boyle's law is applicable to human breathing. To breathe in, one expandstheir rib cage to increase its volume so that the pressure inside theirlungs can decrease. Once the pressure inside the lungs becomes lowerthan the atmospheric pressure, air molecules are able to rush in throughthe person's nostrils. Similarly, to breathe out, one must contracttheir rib cage to decrease its volume so that the pressure inside theirlungs can become greater. Once the pressure inside the lungs becomesgreater than the atmospheric pressure, air molecules are able to rushout through their nostrils. The pressure (P) of gas is inverselyproportional to the volume (V) of gas. This means that as one hold'stemperature (T) and amount (n) of fluid constant (same), as the pressureof gas molecules increase, the volume of gas molecules decreases. P=K/V

FIG. 6A and gB illustrates the LP being positioned further down withrespect to the housing and MRC. One non-limiting embodiment forpositioning the LP as seen in FIGS. 6A and 6B includes using a spring(600) that can be contracted and a miniature electromagnet (601) havinga shaft that can be extended when the inhaler is not in use. When themedication is in MRC (102B) the microcontroller can activate theelectromagnet (601) causing the shaft of the electromagnet to retractwhich causes spring (600) to expand and pushing down LP (101 b) furtherdown or into MRC (102B). In a non-limiting alternative embodiment,spring 600 can be removed where a more powerful or stronger pullingforce electromagnet (601) is provided that can consume more energy. Themovement of the LP down to the MRC can be made with other components,such as, without limitation, magnetic components, etc. like magneticetc. With reference to FIGS. 6A and 6B, application of Boyle's lawyields P1V1=P2V2; P1<P2 and V1>V2 (with P=pressure and V=volume).

Indications can be made by patient physician where medications aredelivered to patient's respiratory system via inhalation device. Primaryuse cases can be respiratory diseases such as, without limitation,Asthma and COPD. Other extended or intended use can be medications forDiabetes, cancer, neurological disorders, neurodegenerative disorders,immunological disorders, and other diseases through which futureresearch and development deemed to have more efficacy and potencythrough delivery by inhalation

One non-limiting advantage of the disclosed electronic inhaler having anembedded system is the airflow, which can serve as the main source ofenergy. The inhaler can be preferably breath actuated, which caninherently avoid the need for the user/patient to synchronize his or heractuation and inspiration maneuver/movements.

Another non-limiting advantage of the disclosed electronic inhalerhaving an embedded system is a relatively low air-flow resistance makingthe inhaler easy to be used by young children and the elderly.

Other non-limiting advantages include:

-   a. Easy to handle;-   b. Accurate dosage counter;-   c. Minimizes deposits;-   d. Improve the flow of particles into the entire patient/user's    respiratory system; and-   e. Feedback to patient, doctor/pharmacist regarding the dose being    successfully administered, scheduled, etc.

Additional non-limiting features, benefits and/or advantages of thedisclosed novel inhaler include:

-   -   1. The inhaler can be designed to accommodate and receive both        dry powder and liquid/spray medications at the same time, with        each medication cartridge/cylinder being received within the        inhaler's chamber and each having its own launch pads. Each        launch pad can be automated upon user inhalation to move forward        into the mouthpiece during inhalation and retract back to its        original position once the prescribed amount of drug has been        delivered. This action helps to prevent or reduce drug residuals        left in the mouthpiece.    -   2. In view of the size of the receiving chambers, the cartridges        can come in preferably three (though not limiting) different        sizes, small, medium, and large. The size of the cartridge        needed can depend of the quantity of drugs and dosage        amount/duration based on the prescription.    -   3. The cartridges can have sensors to communicate to the        microprocessor and/or software app the amount of medicine        available after each dosage has been taken by the user. The        software app can also be programmed to automatically send alerts        to the user's doctor and/or pharmacy when the software app        learns from the received sensor information that the remaining        drug level within the cartridge correlates to 50% use and 75%        usage (though the range is not considered limiting) so that more        medication can be ordered.    -   4. The user's doctor can be provided with the ability to        increase or decrease the dosage amount as needed simply by        logging in to the software. The software can communicate with        the user's app and/or directly with the microprocessor in the        inhaler to make the dosage adjustment.    -   5. Can allow for elimination of the use of spacers in the        inhaler delivery system.    -   6. Three (though not limiting) different thrust levels based on        patient's ability to inhale.    -   7. An inhalation test can be performed with no cartridges in the        device. This information can be used for calibrating and        calculations when setting up the inhaler for automated thrust        level. Using the information from the inhalation test, the        inhaler can be set up with a thrust level that best delivers the        medicine to the user's lungs.    -   8. The inhaler provides for an efficient mode to administer        liquid and/or powder medicine and allows for precise dose        administration and consistency.    -   9. The design of the inhaler allows for efficient delivery of        liquid and/or powder medication under controlled pressure and        velocity.    -   10. The delivery of the medication can be on fast short        sequences preferably based on five different frequencies (though        not limiting) that can be chosen in relation with fluid density.    -   11. The design provides for unique inhalation control using the        aerodynamics of the launch pad design and the influence at the        atomic and molecular levels of the fluid, characterized by low        airflow resistance and a smooth increase of pressure at higher        flow rates during inhalation.    -   12. The design provides for a Vortex effect to be created when        the fluid passes through the launch pad and based on the chosen        frequency for the sequence delivery of the fluid.    -   13. The inhaler addresses deagglomeration by incorporating a        homogenized area. The aerodynamic effect against the fluid mix        can be achieved using cavities and the chamber's geometry;        resulting in a torsional vortex being created in two different        designs.    -   14. The inhaler can be provided with three sources of energy; a)        patient inspiratory airflow; b) airflow from a miniature turbine        preferably powered by one or more batteries; and (c) compression        from moving the launch pad down into the measured reservoir        compartment of the inhaler.    -   15. The inhaler delivers the medication by proximity sensor        controlled by the inhaler's microprocessor.

The disclosed novel inhaler design addresses or reduces the followinglimitations/problems with current inhalers:

-   -   1. The inhaler is relatively easy to use by young children and        the elderly as compared to existing inhalers. Additionally, the        patient is not required to perform any synchronization between        their breath and activation/release of the medication (i.e.        pressing of any button).    -   2. The inhaler allows for the delivered medication to preferably        go down on the low side of the user's lungs and thus eliminating        and/or significantly reducing the deposit of medication on the        user's mouth and/or the cooling effect found with existing        inhalers.    -   3. The inhaler provides for a more precise dose amount of drug        administering.    -   4. Through the algorithm/software and intelligence, the inhaler        helps to eliminate the possibility of the user repeating taken        the same dose.    -   5. The inhaler preferably provides for live feedback for the        patient and doctor, and in certain situations also with the        user's pharmacy.    -   6. The inhaler can be used for liquid and powder medications,        with both types of medication cartridges being able to be housed        within the inhaler at the same time.    -   7. Given that the same inhaler can be used for both liquid and        powder medications, the novel disclosed inhaler design        eliminates the need for the patient/user who needs to take a        liquid medication and a powder medication to have to learn to        operate two or more different devices, with each inhaler having        different operating instructions.

The disclosed electronic inhaler having an embedded system may includethe following components as shown in the drawings with the followingreference numerals: (as in FIG. 1 and FIG. 1A)

-   100—inhaler housing:-   104 a and 104 b—cartridges medicine reservoirs, containers, capsule    compartments-   103—cartridge information sensors (i.e. memory IC located on the    cartridge)-   103 r—sensors for reading cartridge information preferably connected    to microcontroller and located on the device house.-   102 a and 102 b—measuring reservoir compartments (“MRC”).-   101 a and 101 b—launch pads (“LP”)-   150 and 151—injection/ejection mechanism valves-   110—flow control valves-   106—electronic board with microcontroller and wireless communication    module-   107—vibrator mixer for medicine-   108—batteries and charger circuit-   200—aperture airflow, turbine, mass air sensor-   201—air passageway-   109—pressure, vacuum, differential pressure sensors-   119—trigger switch sensor-   99—mouthpiece-   98—homogenized area-   137—internal barriers-   129—wall barriers-   131—central opening

With respect to the embodiment shown in FIG. 8 for modular electronicinhaler 800 having an embedded system may include, without limitation,the following components/parts and be assigned the following referencenumbers:

-   800 modular electronic inhaler-   803 MDI inhaler housing (preferably removable)-   805 DPI inhaler housing (preferably removable)-   801 electronics/electronic housing-   804 a and 804 b cartridges, medicine reservoirs, and/or containers,    etc.-   820 a and 820 b measuring reservoir compartment (MRC)-   860 flow medicine control valve-   850 and 851 injection/ejection mechanism valves-   810 a and 810 b launch pads (LP)-   830 air passageway, aperture airflow-   870 turbine, preferably a mini turbine-   809 pressure, vacuum, and/or differential pressure sensors-   898 homogenized area-   802 mouthpieces (preferably removable)-   835 piston-solenoid actuated-   836 solenoid-   840—cartridge information tag, label, chip, IC, memory, other analog    or digital information storage device (i.e. memory IC located on the    cartridge, etc.) (all collectively referred to as “Cartridge    Information Device)-   840 r—sensors for reading cartridge information preferably connected    to microcontroller and located on the device housing.-   841—angle between the device houses (vertical) and the exit to the    mouthpieces.-   875—air flow sensor or mass air flow sensor.-   877—barriers/obstructions-   878—one way valve

Preferably, all of the electronics components, microcontroller 831,batteries and charging circuit, trigger switch, communicationtechnology, etc. will be located on or within the electronic housing 801(See FIG. 8) of modular electronic inhaler 800.

One difference between the embodiment shown in FIG. 8 and theembodiments shown and described in the earlier Figures is the separationof the pathway of medicine delivery, with the embodiment of FIG. 8having two separate medicine delivery pathways along with two separatemouthpieces, which can be preferably removable mouthpieces 802. Thefirst pathway of the two separate pathways can be defined by MDI inhalerhousing 803 and the second pathway of the two separate pathways can bedefined by DPI inhaler housing 805. As seen in FIG. 8, each housing 803and 805 has its own independent air passageway 830 and its ownmicroturbine 870.

Preferably, neither of the launch pads 810 a and 810 b in the embodimentshown in FIG. 8 move up and/or down towards the measurement reservoircompartment (MRC), in contrast to one or more of the earlier embodimentsfor the inhaler described above.

Piston 835 which preferably compresses the medication within MRC 820 ais preferably designed and/or used with DPI medication housing 805 andcan be preferably actuated by a solenoid 836 (i.e. relatively smallsolenoid) which is preferably controlled by electronics 801.

For the embodiment shown in FIG. 8, homogenized areas 898 comprises twoseparate homogenizing areas. The role and functionality of thehomogenized areas 898 will be similar to the homogenized areas describedabove for earlier embodiments.

Modular inhaler 800, preferably shares common electronics 801 andbattery power (preferably also contained within the housing forelectronics 801, for MDI cartridge/housing 803 and DPI cartridge/housing805. Preferably, the DPI and MDI systems can share an electronics pack,but can be preferably provided with own separate airways 830 andmouthpieces 802. Mouthpiece can be preferably for either the DPI airway830 and/or the MDI airway 830, such that any remaining medicationdeposits and/or any hygiene concerns for inhaler 800 can be addressedthrough replacement of mouthpiece 802 with a new mouthpiece 802.Accordingly, inhaler 800 can be designed such that it is flexible forany configuration, based on needs.

Though, FIG. 8 shows a modular/dual configuration inhaler, it is alsowithin the scope of the disclosure to provide for an inhaler havingeither single medication MDI housing 803/assembly withelectronics/electronic housing 801 or single medication DPI housing805/assembly with electronics/electronic housing 801. It is also withinthe scope of the disclosure to have two MDI housings 803/assemblies withelectronic/electronic housing 801 or two DPI housings 805/assemblieswith electronic/electronic housing 801.

All necessary mechanical and electrical systems can be integrated intothe various housings 801, 803 and/or 805. Preferably, in the modularconfiguration seen in FIG. 8, the mechanical systems for MDI 803 and DPI805 are located separate from each other and are also located separatefor electronic/electronic housing 801. This preferred configurationallows for optimization of the systems, modularity, and improvedcleanliness for inhaler 800.

Pressure/vacuum sensors 809 can be preferably located at or near the endof homogenized areas (898 and beginning of mouthpieces 802. Sensors 802can be preferably in electronic communication the microcontroller forinhaler 800, with the microcontroller preferably contained withinelectronics housing 801.

Actuator valves 850 and 851 can be preferably located at and/or near thebeginning of launch pads (LP) 810 a and 810 b, respectively, and can bepreferably directly coupled at or near an aperture associated with LP810 a and an aperture associated with LP 810 b (See FIG. 8).

The microcontroller of inhaler 800 can also control the on/offconditions/states of actuator valves 850 and 851. In one non-limitingembodiment, control can be accomplished by the microcontroller allowingthe ejection of fluid on fast short sequences. Though not limiting, themicrocontroller can preferably have 5 different frequencies in memoryand an algorithm can pick which frequency to use based on the size ofFine Particles Fraction (F.P.F.) dose prescribed. A higher or lowernumber of frequency choices above 5 frequencies can also be use and arealso considered within the scope of the disclosure.

Novel inhaler 800 preferably addresses deagglomeration through ahomogenized or open/cavity (collectively “homogenized”) area 898.Preferably, the geometric design/configuration of inhaler 800 for thefunctional parts on the exit side of launch pads 810 a and 810 b can beinfluenced by the airflow coming from apertures 830 and mini turbines870. With one aperture 830 and turbine 870 (preferably “mini turbine”and located within the aperture 830) associated with launch pad 810 aand a separate aperture 830 and separate turbine 870 (preferably “miniturbine and located within the aperture 830. Turbines 870 help to createa low resistance for the medication flow. In this way the aerodynamicbehavior of powder particles can be changed, and they may be homogenizedfor the processes of inhalation by the user.

An aerodynamic effect against the fine particle fraction of mix can bepreferably achieved based on the internal cavities and chambersgeometric design (i.e. based on Coanda effect), which is illustrated onhomogenized area 898 of FIG. 1) and also applicable to embodiment shownin FIG. 8. The Coanda effect can be created by the interaction of forcesof airflow from aperture 830 with help from mini turbine 870 and thepowder exiting launch pad 810 a or 810 b, along with the geometry and/ornon-linear internal wall design of the homogenizing areas 898 (as wellas the pulsing of the opening of the valves 850 and 851 by themicrocontroller), which preferably combined results in a torsionalvortex.

In accordance with embodiments of the disclosure, a Mass Air Flow Sensoror Air Flow Sensor 875 can be preferably located within theaperture/passageway 830 preferably before or in front of mini turbine870. Sensor 875 can be in direct communication with the microcontrollerto increase the precision on reading the flow throughaperture/passageway 830.

The inhaler device can preferably include an aperture 830 at theopposite side of mouthpiece and provide a passageway and communicationbetween aperture 830 and homologizing area 898 in communication withmouthpiece 802. Preferably a separate aperture/passageway 830, turbine870 and mouthpiece 802 will be provided for MDI housing 803 and aseparate aperture/passageway 830, turbine 870 and mouthpiece 802 will beprovided for DPI housing 805. Each aperture/passageway 830 with miniturbine 870 can contribute to the creation of a flow of air when theprocess of inhalation is started by the user, such that resistance isreduced resulting in an “easier to use” inhaler 800.

For providing an inhaler with reduced resistance, to provide the userwith a smoother and easier inhalation, the fluid (as defined above)traveling path from the point of leaving valve 850 or 851 through theexit of mouthpiece 802 preferably uses a maximum, or near maximum, ofgravitation forces. Thus, an angle, preferably in the range of about 120degrees to 140 degrees (though not considered limiting and other rangescan be selected and are considered within the scope of the disclosure)for both the position of MDI housing 803 and DPI housing 805 withrespect to their associated apertures/passageways 830 and mouthpieces802. These preferred obtuse angles, as compared to a right angle, allowfor more of gravity's force to affect the medication path/flow andreduce, if not eliminate, accumulation of medication in a corner of themedication path. However, the angle or range of angles selected for MDIhousing 803 does not have to be the same value or values selected forthe angle or range of angles selected for DPI housing 805. In onenon-limiting embodiment, the angle selected for MDI housing 803 can bean or about 120 degree angle 841.

Mini turbine 870 can be actuated and turned on by the microcontrollerfrom a signal sent from sensor 809 to the microcontroller after themicrocontroller senses or detects a vacuum condition. The sensing canoccur preferably and virtually simultaneously with electronicalactivation of inhaler 800. Based on the readings of air flow sensor 875the microcontroller can increase or decrease the speed rotation of miniturbine 870, thus, increasing or decreasing the air flow sent to theappropriate homogenize area 898.

Another novel aspect or feature for one or more of the inhaler(s)disclosed herein can be directed to the way the inhaler creates moreenergy for medication delivery, preferably with respect to the DPI side(i.e. since the MDI side already preferably uses a cartridge built underpressure). Using inhaler 800 as an example, compression can be createdon MRC 820 a, using piston 835 which can be preferably actuated byrelatively small solenoid 836. Thus, using piston 835 pressure in MRC820 a can be increased, which in addition to gravity (i.e. based on theposition of inhaler 800 and the placement position of the cartridgeapplying gravitational force on the medication), and an increase of thepressure of medicine delivery can occur preferably and virtuallysimultaneously with a Bernoulli effect created on LP 810 a. When themedication is in MRC 820 a the microcontroller can activate thesolenoid/electromagnetic activation 836 causing the shaft of theelectromagnet/solenoid to expand and pushing the piston 835 on the sidefurther left within MRC 820 a.

FIG. 9 illustrates another embodiment for a modular electronic inhalerand is generally designated as inhaler 900. Inhaler 900 is similar toinhaler 800 in function and operation. However, inhaler has a singleaperture 830 located near the cartridge entry points. The internalpassageway remains a single passageway along the or virtually parallelwith housings 803 and 805 and then forms two separate passageways, oneleading to mouthpiece 802 associated with housing 803 and one leading tomouthpiece 802 associated with housing 805. As seen in FIG. 9, a singleturbine 870 is also preferred and disposed within the single internalpassageway portion. However, it is also within the scope of thedisclosure to place a first turbine 870 into the passageway portionleading to housing 803 mouthpiece 802 and a second turbine 870 into thepassageway portion leading to housing 805 mouthpiece 802. A one wayvalve 878 (e.g. flap, etc.) can be preferably located at the point orarea where the single passageway branches out into a first auxiliarypassageway associated with housing 803 and a second auxiliary passagewayassociated with housing 805. Valve 878 preferably allows only one of theauxiliary passageways to be in communication with the single passagewayat a time. Accordingly, when using inhaler 900 for receiving powdermedication (i.e. using DPI housing 805 and associatedassembly/mouthpiece), valve 878 blocks air coming from the singlepassageway from entering the first auxiliary passageway associated withhousing 803. Similarly, when using inhaler 900 to receive liquidmedication (i.e. using MDI housing 803 and associatedassembly/mouthpiece), valve 878 blocks air coming from the singlepassageway from entering the second auxiliary passageway associated withhousing 805. Preferably, the operation and positioning of valve 878 canbe controlled by the microcontroller.

All components of the disclosed novel electronic inhaler and theircommunication methods and technologies, materials, construction, sizes,cartridge sizes, shapes, cartridge shapes, cartridge selections andopening mechanisms, medication types and forms, etc. discussed aboveand/or shown in the drawings, are merely by way of example and are notconsidered limiting and other component(s) and their communicationmethods and technologies, materials, construction, sizes, cartridgesizes, shapes, cartridge shapes, cartridge selections and openingmechanisms, medication types and forms, etc. currently known and/orlater developed can also be chosen and used and all are consideredwithin the scope of the disclosure.

All measurements, amounts, frequencies, voltages, intensity amounts,sizes, shapes, percentages, configurations, securement or attachmentmechanisms, dimensions, filtration mechanisms, sealing members, numbers,ranges, part locations, values, percentages, magnet types, sensor types,data readers, materials, orientations, methods of manufacture, etc.discussed above or shown in the drawing figures are merely by way ofexample and are not considered limiting and other measurements, amounts,frequencies, voltages, intensity amounts, sizes, shapes, percentages,configurations, securement or attachment mechanisms, dimensions,filtration mechanisms, sealing members, numbers, ranges, part locations,values, percentages, magnet types, system types, data readers,materials, orientations, methods of manufacture, etc. can be chosen andused and all are considered within the scope of the disclosure.

Furthermore, one or more features, components, characteristics, parts,uses, etc. discussed for one embodiment of the disclosure can also beused with another of the above discussed embodiments of the disclosureand the description and function of the feature, components,characteristic, parts, uses, etc. for one embodiment is incorporated byreference into the other embodiment(s) where the feature, component,characteristic, parts, uses, etc. are described or can also be found.

Additionally, for any numerical ranges discussed above, any combinationof numbers within the range can be used to create a smaller size rangefrom the outer limits of the numerical range specified and all suchsmaller ranges are also considered to be within the scope of thedisclosure and also incorporated by reference without particularlylisting each specific numerical value for the smaller ranges.

Unless feature(s), part(s), component(s), characteristic(s) orfunction(s) described in the specification or shown in the drawings fora claim element, claim step or claim term specifically appear in theclaim with the claim element, claim step or claim term, then theinventor does not considered such feature(s), part(s), component(s),characteristic(s) or function(s) to be included for the claim element,claim step or claim term in the claim for examination purposes and whenand if the claim element, claim step or claim term is interpreted orconstrued. Similarly, with respect to any “means for” elements in theclaims, the inventor considers such language to require only the minimalamount of features, components, steps, or parts from the specificationto achieve the function of the “means for” language and not all of thefeatures, components, steps or parts describe in the specification thatare related to the function of the “means for” language.

While the disclosure has been described and disclosed in certain termsand has disclosed certain embodiments or modifications, persons skilledin the art who have acquainted themselves with the disclosure, willappreciate that it is not necessarily limited by such terms, nor to thespecific embodiments and modification disclosed herein or shown in thedrawings. Thus, a wide variety of alternatives, suggested by theteachings herein, can be practiced without departing from the spirit ofthe disclosure, and rights to such alternatives are particularlyreserved and considered within the scope of the disclosure.

What is claimed is:
 1. An electronic inhaler comprising: a first housinghaving a first end and a second end and defining a first medicationpassageway from the first end to the second end, the first housingdefining a first homogenizing area at or near the second end of thefirst housing, the first medication passageway terminating into thefirst homogenizing area, a first end portion of the first medicationpassageway defining a first cartridge compartment; a second housinghaving a first end and a second end and defining a second medicationpassageway from the first end to the second end of the second housing,the second medication passageway separate and independent from the firstmedication passageway, the second housing defining a second homogenizingarea at or near the second end of the second housing, the secondmedication passageway terminating into the second homogenizing area, afirst end portion of the second medication passageway defining a secondcartridge compartment; a first measuring reservoir compartment (“firstMRC”) disposed within an intermediate portion of the first medicationpassageway or defined by the intermediate portion of the firstmedication passageway; a second measuring reservoir compartment (“secondMRC”) disposed within an intermediate portion of the second medicationpassageway or defined by the intermediate portion of the secondmedication passageway; a first launch pad (“first LP) disposed betweenthe first MRC and the first homogenizing area, the first LP having anexit end in communication with the first homogenizing area; a secondlaunch pad (“second LP”) disposed between the second MRC and the secondhomogenizing area, the second LP having an exit end in communicationwith the second homogenizing area; and a microcontroller for controllingoperation of the electronic inhaler; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;wherein the microcontroller is disposed within an electronic housingwhich is separate from the first housing and the second housing; whereinthe electronic housing is disposed between the first housing and thesecond housing.
 2. The electronic inhaler of claim 1 further comprisinga removable mouthpiece either disposed at the second end of the firsthousing such that the mouthpiece surrounds the first homogenizing areawhen the mouthpiece is disposed at the second end of the first housingor disposed at the second end of the second housing such that themouthpiece surrounds the second homogenizing area when the mouthpiece isdisposed at the second end of the second housing.
 3. The electronicinhaler of claim 2 further comprising one or more sensors disposedwithin or near the mouthpiece and in communication with themicrocontroller to inform the microcontroller when a user inhales usingthe electronic inhaler.
 4. The electronic inhaler of claim 1 wherein thefirst housing is non-linear from the first end to the second end of thefirst housing and a medication exit portion of the first housing isdisposed at a first angle with respect to a medication inlet portion ofthe first housing and wherein the second housing is non-linear from thefirst end to the second end of the second housing and a medication exitportion of the second housing is disposed at a second angle with respectto a medication inlet portion of the second housing.
 5. The electronicinhaler of claim 4 wherein the first angle is selected from a range ofabout 120 degrees to about 140 degrees.
 6. The electronic inhaler ofclaim 1 further comprising a first cartridge data reader adapted to reador receive information from a cartridge disposed within the firstcartridge compartment and a second cartridge data reader adapted to reador receive info information from a cartridge disposed within the secondcartridge compartment.
 7. An electronic inhaler comprising: a firsthousing having a first end and a second end and defining a firstmedication passageway from the first end to the second end, the firsthousing defining a first homogenizing area at or near the second end ofthe first housing, the first medication passageway terminating into thefirst homogenizing area, a first end portion of the first medicationpassageway defining a first cartridge compartment; a second housinghaving a first end and a second end and defining a second medicationpassageway from the first end to the second end of the second housing,the second medication passageway separate and independent from the firstmedication passageway, the second housing defining a second homogenizingarea at or near the second end of the second housing, the secondmedication passageway terminating into the second homogenizing area, afirst end portion of the second medication passageway defining a secondcartridge compartment; a first measuring reservoir compartment (“firstMRC”) disposed within an intermediate portion of the first medicationpassageway or defined by the intermediate portion of the firstmedication passageway; a second measuring reservoir compartment (“secondMRC”) disposed within an intermediate portion of the second medicationpassageway or defined by the intermediate portion of the secondmedication passageway; a first launch pad (“first LP) disposed betweenthe first MRC and the first homogenizing area, the first LP having anexit end in communication with the first homogenizing area; a secondlaunch pad (“second LP″) disposed between the second MRC and the secondhomogenizing area, the second LP having an exit end in communicationwith the second homogenizing area; and a microcontroller for controllingoperation of the electronic inhaler; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;further comprising a first mouthpiece disposed at the second end of thefirst housing such that the first mouthpiece surrounds the firsthomogenizing area when the first mouthpiece is disposed at the secondend of the first housing and a second mouthpiece disposed at the secondend of the second housing such that the second mouthpiece surrounds thesecond homogenizing area when the second mouthpiece is disposed at thesecond end of the second housing.
 8. The electronic inhaler of claim 7wherein the microcontroller is disposed within an electronic housingwhich is separate from the first housing and the second housing.
 9. Theelectronic inhaler of claim 7 further comprising one or more sensorsdisposed within or near the first mouthpiece and in communication withthe microcontroller to inform the microcontroller when a user inhalesthrough the first mouthpiece and one or more sensors disposed within ornear the second mouthpiece and in communication with the microcontrollerto inform the microcontroller when the user inhales through the secondmouthpiece.
 10. An electronic inhaler comprising: a first housing havinga first end and a second end and defining a first medication passagewayfrom the first end to the second end, the first housing defining a firsthomogenizing area at or near the second end of the first housing, thefirst medication passageway terminating into the first homogenizingarea, a first end portion of the first medication passageway defining afirst cartridge compartment; a second housing having a first end and asecond end and defining a second medication passageway from the firstend to the second end of the second housing, the second medicationpassageway separate and independent from the first medicationpassageway, the second housing defining a second homogenizing area at ornear the second end of the second housing, the second medicationpassageway terminating into the second homogenizing area, a first endportion of the second medication passageway defining a second cartridgecompartment; a first measuring reservoir compartment (“first MRC”)disposed within an intermediate portion of the first medicationpassageway or defined by the intermediate portion of the firstmedication passageway; a second measuring reservoir compartment (“secondMRC”) disposed within an intermediate portion of the second medicationpassageway or defined by the intermediate portion of the secondmedication passageway; a first launch pad (“first LP) disposed betweenthe first MRC and the first homogenizing area, the first LP having anexit end in communication with the first homogenizing area; a secondlaunch pad (“second LP″) disposed between the second MRC and the secondhomogenizing area, the second LP having an exit end in communicationwith the second homogenizing area; and a microcontroller for controllingoperation of the electronic inhaler; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;further comprising a first valve for controlling communication betweenthe first MRC and the first cartridge when the first cartridge isdisposed within the first cartridge compartment, a second valve forcontrolling communication between the second MRC and the secondcartridge when the second cartridge is disposed within the secondcartridge compartment, a third valve for controlling communicationbetween the first MRC and the first LP and a fourth valve forcontrolling communication between the second MRC and the second LP. 11.The electronic inhaler of claim 10 wherein operation of the first valve,second valve, third valve and fourth valve are controlled by themicrocontroller.
 12. The electronic inhaler of claim 10 wherein themicrocontroller is programmed to cause the first valve to be in an openposition for a specific amount of time to permit a precise amount ofcontent to flow from the first cartridge into the first MRC or to causethe second valve to be in an open position for a specific amount of timeto permit a precise amount of content to flow from the second cartridgeinto the second MRC.
 13. The electronic inhaler of claim 12 wherein themicrocontroller is programmed to cause either the third valve to be inan open position for a specific amount of time to permit a preciseamount of content contained with the first MRC to flow to the first LPor to cause the fourth valve to be in an open position for a specificamount of time to permit a precise amount of content contained with thesecond MRC to flow to the second LP.
 14. An electronic inhalercomprising: a first housing having a first end and a second end anddefining a first medication passageway from the first end to the secondend, the first housing defining a first homogenizing area at or near thesecond end of the first housing, the first medication passagewayterminating into the first homogenizing area, a first end portion of thefirst medication passageway defining a first cartridge compartment; asecond housing having a first end and a second end and defining a secondmedication passageway from the first end to the second end of the secondhousing, the second medication passageway separate and independent fromthe first medication passageway, the second housing defining a secondhomogenizing area at or near the second end of the second housing, thesecond medication passageway terminating into the second homogenizingarea, a first end portion of the second medication passageway defining asecond cartridge compartment; a first measuring reservoir compartment(“first MRC”) disposed within an intermediate portion of the firstmedication passageway or defined by the intermediate portion of thefirst medication passageway; a second measuring reservoir compartment(“second MRC”) disposed within an intermediate portion of the secondmedication passageway or defined by the intermediate portion of thesecond medication passageway; a first launch pad (“first LP) disposedbetween the first MRC and the first homogenizing area, the first LPhaving an exit end in communication with the first homogenizing area; asecond launch pad (“second LP”) disposed between the second MRC and thesecond homogenizing area, the second LP having an exit end incommunication with the second homogenizing area; and a microcontrollerfor controlling operation of the electronic inhaler; wherein the firstcartridge compartment is adapted for receipt of a first cartridge andthe second cartridge compartment is adapted for receipt of a secondcartridge; further comprising a first air opening and passagewaydisposed at or near the second end of the first housing and a second airopening and passageway disposed at or near the second end of the secondhousing.
 15. The electronic inhaler of claim 14 wherein an exit end ofthe first air opening and passageway terminate into the firsthomogenizing area and an exit end of the second air opening andpassageway terminate into the second homogenizing area.
 16. Theelectronic inhaler of claim 15 wherein in use upon inhalation by a userand based on a positional relationship between the first homogenizingarea with an exit area of the first LP and the first air passageway anda positional relationship between the second homogenizing area with anexit area of the second LP and the second air passageway either (i) airentering through the first air opening and passageway and receivedwithin the first homogenizing area interacts with an amount ofmedication received into the first homogenizing area from the first LPto create a torsional vortex, or (ii) air entering through the secondair opening and passageway and received within the second homogenizingarea interacts with an amount of medication received into the secondhomogenizing area from second LP to create a torsional vortex.
 17. Theelectronic inhaler of claim 14 further comprising a first turbinedisposed within the first air opening and passageway and a secondturbine disposed within the second air opening and passageway; whereinoperation of the first turbine and the second turbine is controlled bythe microcontroller.
 18. An electronic inhaler comprising: a firsthousing having a first end and a second end and defining a firstmedication passageway from the first end to the second end, the firsthousing defining a first homogenizing area at or near the second end ofthe first housing, the first medication passageway terminating into thefirst homogenizing area, a first end portion of the first medicationpassageway defining a first cartridge compartment; a second housinghaving a first end and a second end and defining a second medicationpassageway from the first end to the second end of the second housing,the second medication passageway separate and independent from the firstmedication passageway, the second housing defining a second homogenizingarea at or near the second end of the second housing, the secondmedication passageway terminating into the second homogenizing area, afirst end portion of the second medication passageway defining a secondcartridge compartment; a first measuring reservoir compartment (“firstMRC”) disposed within an intermediate portion of the first medicationpassageway or defined by the intermediate portion of the firstmedication passageway; a second measuring reservoir compartment (“secondMRC”) disposed within an intermediate portion of the second medicationpassageway or defined by the intermediate portion of the secondmedication passageway; a first launch pad (“first LP) disposed betweenthe first MRC and the first homogenizing area, the first LP having anexit end in communication with the first homogenizing area; a secondlaunch pad (“second LP″) disposed between the second MRC and the secondhomogenizing area, the second LP having an exit end in communicationwith the second homogenizing area; and a microcontroller for controllingoperation of the electronic inhaler; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;further comprising an air opening and passageway extending downward fromthe first end of the first housing and the first end of the secondhousing and splitting into a first auxiliary passageway that terminatesinto the first homogenizing area and a second auxiliary passageway thatterminates into the second homogenizing area.
 19. The electronic inhalerof claim 18 further comprising a turbine disposed within the air openingand passageway; wherein operation of the turbine is controlled by themicrocontroller.
 20. An electronic inhaler comprising: a first housinghaving a first end and a second end and defining a first medicationpassageway from the first end to the second end, the first housingdefining a first homogenizing area at or near the second end of thefirst housing, the first medication passageway terminating into thefirst homogenizing area, a first end portion of the first medicationpassageway defining a first cartridge compartment; a second housinghaving a first end and a second end and defining a second medicationpassageway from the first end to the second end of the second housing,the second medication passageway separate and independent from the firstmedication passageway, the second housing defining a second homogenizingarea at or near the second end of the second housing, the secondmedication passageway terminating into the second homogenizing area, afirst end portion of the second medication passageway defining a secondcartridge compartment; a first measuring reservoir compartment (“firstMRC”) disposed within an intermediate portion of the first medicationpassageway or defined by the intermediate portion of the firstmedication passageway; a second measuring reservoir compartment (“secondMRC”) disposed within an intermediate portion of the second medicationpassageway or defined by the intermediate portion of the secondmedication passageway; a first launch pad (“first LP) disposed betweenthe first MRC and the first homogenizing area, the first LP having anexit end in communication with the first homogenizing area; a secondlaunch pad (“second LP”) disposed between the second MRC and the secondhomogenizing area, the second LP having an exit end in communicationwith the second homogenizing area; and a microcontroller for controllingoperation of the electronic inhaler; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;further comprising at least one first barrier disposed within the firsthomogenizing area in proximity to an exit end of the first LP and atleast one second barrier disposed within the second homogenizing area inproximity to an exit end of the second LP; wherein the at least onefirst barrier creates a first partially obstructed medication travelpath and the at least one second barrier creates a second partiallyobstructed medicated travel path; wherein in use medication leaving thefirst LP travels through the first partially obstructed medicationtravel path before exiting the homogenizing area or medication leavingthe second LP travels through the second partially obstructed medicationtravel path before exiting the homogenizing area.
 21. An electronicinhaler comprising: a first housing having a first end and a second endand defining a first medication passageway from the first end to thesecond end, the first housing defining a first homogenizing area at ornear the second end of the first housing, the first medicationpassageway terminating into the first homogenizing area, a first endportion of the first medication passageway defining a first cartridgecompartment; a second housing having a first end and a second end anddefining a second medication passageway from the first end to the secondend of the second housing, the second medication passageway separate andindependent from the first medication passageway, the second housingdefining a second homogenizing area at or near the second end of thesecond housing, the second medication passageway terminating into thesecond homogenizing area, a first end portion of the second medicationpassageway defining a second cartridge compartment; a first measuringreservoir compartment (“first MRC”) disposed within an intermediateportion of the first medication passageway or defined by theintermediate portion of the first medication passageway; a secondmeasuring reservoir compartment (“second MRC”) disposed within anintermediate portion of the second medication passageway or defined bythe intermediate portion of the second medication passageway; a firstlaunch pad (“first LP) disposed between the first MRC and the firsthomogenizing area, the first LP having an exit end in communication withthe first homogenizing area; a second launch pad (“second LP″) disposedbetween the second MRC and the second homogenizing area, the second LPhaving an exit end in communication with the second homogenizing area;and a microcontroller for controlling operation of the electronicinhaler; wherein the first cartridge compartment is adapted for receiptof a first cartridge and the second cartridge compartment is adapted forreceipt of a second cartridge; wherein an internal diameter of the firstLP is greater in size at a first inlet end of the first LP as comparedto a second exit end of the first LP and an internal diameter of thesecond LP is smaller in size at a first inlet end of the second LP ascompared to a second exit end of the second LP.
 22. An electronicinhaler comprising: a first housing having a first end and a second endand defining a first medication passageway from the first end to thesecond end, the first housing defining a first homogenizing area at ornear the second end of the first housing, the first medicationpassageway terminating into the first homogenizing area, a first endportion of the first medication passageway defining a first cartridgecompartment; a second housing having a first end and a second end anddefining a second medication passageway from the first end to the secondend of the second housing, the second medication passageway separate andindependent from the first medication passageway, the second housingdefining a second homogenizing area at or near the second end of thesecond housing, the second medication passageway terminating into thesecond homogenizing area, a first end portion of the second medicationpassageway defining a second cartridge compartment; a first measuringreservoir compartment (“first MRC”) disposed within an intermediateportion of the first medication passageway or defined by theintermediate portion of the first medication passageway; a secondmeasuring reservoir compartment (“second MRC”) disposed within anintermediate portion of the second medication passageway or defined bythe intermediate portion of the second medication passageway; a firstlaunch pad (“first LP) disposed between the first MRC and the firsthomogenizing area, the first LP having an exit end in communication withthe first homogenizing area; a second launch pad (“second LP″) disposedbetween the second MRC and the second homogenizing area, the second LPhaving an exit end in communication with the second homogenizing area;and a microcontroller for controlling operation of the electronicinhaler; a first air opening and passageway disposed at or near thesecond end of the first housing and a second air opening and passagewaydisposed at or near the second end of the second housing, an exit end ofthe first air opening and passageway terminating into the firsthomogenizing area and an exit end of the second air opening andpassageway terminating into the second homogenizing area; and a firstturbine disposed within the first air opening and passageway and asecond turbine disposed within the second air opening and passageway;wherein operation of the first turbine and the second turbine iscontrolled by the microcontroller; wherein the first cartridgecompartment is adapted for receipt of a first cartridge and the secondcartridge compartment is adapted for receipt of a second cartridge;wherein in use upon inhalation by a user and based on a positionalrelationship between the first homogenizing area with an exit area ofthe first LP and the first air passageway and a positional relationshipbetween the second homogenizing area with an exit area of the second LPand the second air passageway either (i) air entering through the firstair opening and passageway and received within the first homogenizingarea interacts with an amount of medication received into the firsthomogenizing area from the first LP to create a torsional vortex, or(ii) air entering through the second air opening and passageway andreceived within the second homogenizing area interacts with an amount ofmedication received into the second homogenizing area from second LP tocreate a torsional vortex.
 23. The electronic inhaler of claim 22further comprising a first mouthpiece disposed at the second end of thefirst housing such that the first mouthpiece surrounds the firsthomogenizing area when the first mouthpiece is disposed at the secondend of the first housing and a second mouthpiece disposed at the secondend of the second housing such that the second mouthpiece surrounds thesecond homogenizing area when the second mouthpiece is disposed at thesecond end of the second housing.
 24. The electronic inhaler of claim 22further comprising a first valve for controlling communication betweenthe first MRC and the first cartridge when the first cartridge isdisposed within the first cartridge compartment, a second valve forcontrolling communication between the second MRC and the secondcartridge when the second cartridge is disposed within the secondcartridge compartment, a third valve for controlling communicationbetween the first MRC and the first LP and a fourth valve forcontrolling communication between the second MRC and the second LP;wherein operation of the first valve, second valve, third valve andfourth valve are controlled by the microcontroller.
 25. The electronicinhaler of claim 22 further comprising at least one first barrierdisposed within the first homogenizing area in proximity to an exit endof the first LP and at least one second barrier disposed within thesecond homogenizing area in proximity to an exit end of the second LP;wherein the at least one first barrier creates a first partiallyobstructed medication travel path and the at least one second barriercreates a second partially obstructed medicated travel path; wherein inuse medication leaving the first LP travels through the first partiallyobstructed medication travel path before exiting the homogenizing areaor medication leaving the second LP travels through the second partiallyobstructed medication travel path before exiting the homogenizing area.26. The electronic inhaler of claim 22 wherein an internal diameter ofthe first LP is greater in size at a first inlet end of the first LP ascompared to a second exit end of the first LP and an internal diameterof the second LP is smaller in size at a first inlet end of the secondLP as compared to a second exit end of the second LP.
 27. An electronicinhaler comprising: a first housing having a first end and a second endand defining a first medication passageway from the first end to thesecond end, the first housing defining a first homogenizing area at ornear the second end of the first housing, the first medicationpassageway terminating into the first homogenizing area, a first endportion of the first medication passageway defining a first cartridgecompartment; a second housing having a first end and a second end anddefining a second medication passageway from the first end to the secondend of the second housing, the second medication passageway separate andindependent from the first medication passageway, the second housingdefining a second homogenizing area at or near the second end of thesecond housing, the second medication passageway terminating into thesecond homogenizing area, a first end portion of the second medicationpassageway defining a second cartridge compartment; a first measuringreservoir compartment (“first MRC”) disposed within an intermediateportion of the first medication passageway or defined by theintermediate portion of the first medication passageway; a secondmeasuring reservoir compartment (“second MRC”) disposed within anintermediate portion of the second medication passageway or defined bythe intermediate portion of the second medication passageway; a firstlaunch pad (“first LP) disposed between the first MRC and the firsthomogenizing area, the first LP having an exit end in communication withthe first homogenizing area, an internal diameter of the first LP isgreater in size at a first inlet end of the first LP as compared to asecond exit end of the first LP; a second launch pad (“second LP″)disposed between the second MRC and the second homogenizing area, thesecond LP having an exit end in communication with the secondhomogenizing area, an internal diameter of the second LP is smaller insize at a first inlet end of the second LP as compared to a second exitend of the second LP; a microcontroller for controlling operation of theelectronic inhaler; a first air opening and passageway disposed at ornear the second end of the first housing and a second air opening andpassageway disposed at or near the second end of the second housing, anexit end of the first air opening and passageway terminating into thefirst homogenizing area and an exit end of the second air opening andpassageway terminating into the second homogenizing area; a firstturbine disposed within the first air opening and passageway and asecond turbine disposed within the second air opening and passageway; afirst mouthpiece disposed at the second end of the first housing suchthat the first mouthpiece surrounds the first homogenizing area when thefirst mouthpiece is disposed at the second end of the first housing anda second mouthpiece disposed at the second end of the second housingsuch that the second mouthpiece surrounds the second homogenizing areawhen the second mouthpiece is disposed at the second end of the secondhousing; a first valve for controlling communication between the firstMRC and the first cartridge when the first cartridge is disposed withinthe first cartridge compartment, a second valve for controllingcommunication between the second MRC and the second cartridge when thesecond cartridge is disposed within the second cartridge compartment, athird valve for controlling communication between the first MRC and thefirst LP and a fourth valve for controlling communication between thesecond MRC and the second LP; wherein operation of the first valve,second valve, third valve and fourth valve are controlled by themicrocontroller wherein operation of the first turbine and the secondturbine is controlled by the microcontroller; wherein the firstcartridge compartment is adapted for receipt of a first cartridge andthe second cartridge compartment is adapted for receipt of a secondcartridge; wherein in use upon inhalation by a user and based on apositional relationship between the first homogenizing area with an exitarea of the first LP and the first air passageway and a positionalrelationship between the second homogenizing area with an exit area ofthe second LP and the second air passageway either (i) air enteringthrough the first air opening and passageway and received within thefirst homogenizing area interacts with an amount of medication receivedinto the first homogenizing area from the first LP to create a torsionalvortex, or (ii) air entering through the second air opening andpassageway and received within the second homogenizing area interactswith an amount of medication received into the second homogenizing areafrom second LP to create a torsional vortex.
 28. The electronic inhalerof claim 27 further comprising at least one first barrier disposedwithin the first homogenizing area in proximity to an exit end of thefirst LP and at least one second barrier disposed within the secondhomogenizing area in proximity to an exit end of the second LP; whereinthe at least one first barrier creates a first partially obstructedmedication travel path and the at least one second barrier creates asecond partially obstructed medicated travel path; wherein in usemedication leaving the first LP travels through the first partiallyobstructed medication travel path before exiting the homogenizing areaor medication leaving the second LP travels through the second partiallyobstructed medication travel path before exiting the homogenizing area.